NCOA3 and colorectal carcinoma: Given that cetuximab resistance is primarily dependent on KRAS mutation status, and that we observed enhanced cetuximab resistance upon stable knockdown of FOXO3 and NCOA3 (Fig. 5a), the data strengthen the links between NCOA3 and FOXO3, and the Ras pathway in CRC.